The National Department of Health has pointed to global logistics disruptions, congestion at the Durban harbour and enforcement action against local manufacturers as contributing factors.
By Mapaballo Borotho

Patients at healthcare facilities in Gauteng are struggling to access essential medicines, with shortages affecting those who rely on clinics for treatment of chronic conditions.
Some of these patients in the East of Johannesburg claim they have left clinics without their prescribed medication, forcing some to buy medicines from private pharmacies at an additional cost.
The Gauteng Department of Health has also acknowledged the shortages, saying it is working around the clock to ensure patients are prioritised.
Speaking to Phemelo Motene on Point of View, Chief Director for Health Products Procurement at the National Department of Health, Khadija Jamaloodien, discussed the shortages and what is being done to address them.
Jamaloodien clarified that the medicine shortages are not limited to Gauteng, but are affecting the entire country.
She attributed some of the supply challenges to disruptions in global logistics linked to the conflict involving the United States, Israel and Iran.
“If we look back at what has actually led to where we are now, it is related to the global logistics where there’s supply challenges globally because of the US/Israel war against Iran. The conflict has caused a lot of delays globally, not just in the medicine space,” she said.
She also pointed to congestion at the Durban harbour, where ships have reportedly been unable to offload goods for several weeks.
Another challenge involves enforcement orders issued by the South African Health Products Regulatory Authority (SAHPRA) against some local medicine manufacturers.
Jamaloodien explained that when SAHPRA issues an enforcement order, a manufacturer may be required to halt production until the regulator is satisfied that the necessary requirements have been met.
“What happens when they issue an enforcement is, in some instances that particular manufacturer has to shut down production before SAHPRA allows them to start manufacturing again. This is significant because we want our products manufactured here to be of good quality, safe and effective,” she added.
SAHPRA’s role is to ensure that medicines manufactured and supplied in the country meet the required quality, safety and efficacy standards. Where manufacturers fail to meet these requirements, the regulator can take enforcement action.
Jamaloodien said six manufacturers were currently affected by enforcement action, contributing to supply interruptions for certain medicines.
What is being done to address the shortages?
Jamaloodien said the Gauteng Department of Health had mitigation plans in place to help manage the supply challenges.
She said the department was engaging with SAHPRA to receive information about possible upcoming enforcement actions, as some manufacturers do not communicate with the department after receiving warnings from the regulator.
This, she explained, would help the department prepare and avoid being caught off guard by potential disruptions.
The department is also monitoring medicine availability at both supplier and healthcare facility level.
“So the supplier has to tell us in terms of the content what they have in production and so on whereas in facilities, we monitor what the demand is. One of the things that we do in mitigation of the potential supply challenge is the issue of your high risk items, so if there’s one supplier who cannot supply, we shift the volume to the supplier who can. This is one of the mitigation strategies that we have in place,” she said.
Listen to the podcast for the full conversation with Khadija Jamaloodien and more on the measures being implemented to mitigate medicine shortages.
Kaya 959 podcasts are available to download.
READ NEXT: